Objective: To evaluate the risk factors affecting thromboembolism in lymphoma patients with chemotherapy.
Methods: Three hundred and four consecutive lymphoma patients treated by chemotherapy between January 2012 and July 2019 were enrolled and retrospectively analyzed, consisting of 111 patients with thromboembolism and 193 without thromboembolism. Univariate analysis was used to compare the clinical characteristics and related laboratory examination between the patients, while multivariate Logistic regression analysis were used to identify the risk factors affecting thromboembolism in lymphoma patients with chemotherapy.
Results: Univariate analysis showed that the female, BMI <18.5 or >24, ≥60 years old, with abnormal platelets before chemotherapy, prolonged single hospitalization days and patients at Ann Arbor stage III and IV could increase the incidence of thromboembolism in lymphoma patients treated by chemotherapy. Multivariate Logistic regression analysis showed that abnormal platelet count before chemotherapy, patients at Ann Arbor stage III and IV, and female were all the independent risk factors affecting thromboembolism in lymphoma patients thromboembolism after chemotherapy (P<0.05).
Conclusion: For lymphoma chemotherapy patients, female, abnormal platelet count before chemotherapy and Ann Arbor stages III and IV show a significantly higher risk for thromboembolism. Thus, preventive anticoagulation therapy is recommended.
题目: 淋巴瘤化疗患者发生血栓栓塞症的危险因素分析.
目的: 探讨淋巴瘤化疗患者发生血栓栓塞症（TE）的危险因素.
方法: 回顾性分析2012年1月-2019年7月接受化疗的淋巴瘤患者304例，其中发生TE患者111例，未发生TE患者193例，单因素分析比较两组患者的临床特征资料及相关化验检查，多因素Logistic回归分析淋巴瘤化疗患者发生TE的危险因素.
结果: 单因素分析结果显示，女性、BMI＜18.5 or＞24 、年龄≥60岁、化疗前血小板异常、单次住院天数及Ann Arbor分期为III、IV期患者，均会增高淋巴瘤化疗患者发生TE的风险。多因素Logistic回归分析显示，化疗前血小板数异常、Ann Arbor分期为III、IV期、女性患者等均是影响淋巴瘤患者化疗后发生TE的独立危险因素（P＜0.05）.
结论: 对于淋巴瘤化疗患者，女性、化疗前血小板异常、分期为III、IV患者，其发生血栓栓塞症的风险较其他患者明显增高，对于这部分患者我们建议预防性抗凝治疗.
Keywords: lymphoma; chemotherapy; risk factor; thromboembolism.